2025-07-20 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided. The report is in English, starts with key numerical data, and includes an analysis of each section followed by a comprehensive summary.

**Stock Report: Johnson & Johnson (JNJ)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company that researches, develops, manufactures, and sells a broad range of products in the healthcare field.
*   **JNJ Cumulative Return:** 20.59%
*   **VOO Cumulative Return:** 96.72%
*   **Relative Performance Gap:** -76.1 (Relative Deviation: 6.7)

    *   *Analysis:* JNJ has significantly underperformed the S&P 500 (VOO) over the period examined.  The relative deviation of 6.7 suggests that the current underperformance is near the lower end of its historical range, implying it is significantly below the benchmark.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2015-2017  | 28.0%  | 56.1%  | -1.0%  | -0.0 | 336.2  |
| 2016-2018  | 8.0%   | 56.6%  | -10.0% | 0.0  | 310.5  |
| 2017-2019  | 18.0%  | 56.6%  | -12.0% | 0.7  | 351.0  |
| 2018-2020  | 12.0%  | 59.2%  | -8.0%  | 0.3  | 378.7  |
| 2019-2021  | 32.0%  | 59.6%  | -16.0% | 0.2  | 411.6  |
| 2020-2022  | 7.0%   | 61.4%  | 5.0%   | 0.2  | 425.0  |
| 2021-2023  | -15.0% | 61.4%  | -33.0% | 0.4  | 377.1  |
| 2022-2024  | -35.0% | 61.4%  | -61.0% | 0.3  | 348.0  |
| 2023-2025  | -7.0%  | 70.1%  | -55.0% | 0.2  | 393.9  |

*   *Analysis:*
    *   **CAGR:** The Compound Annual Growth Rate fluctuates significantly, with periods of high growth followed by negative returns.
    *   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk of loss during the analyzed periods.
    *   **Alpha:**  Alpha is largely negative, suggesting underperformance relative to a benchmark.  The negative Alpha is especially pronounced in recent periods.
    *   **Beta:** Beta values are generally low, indicating low volatility relative to the market.

**2. Recent Stock Price Movement**

*   **Current Price:** $163.70
*   **Previous Close:** $162.98
*   **Change:** 0.44 (Positive Change)
*   **5-day Moving Average:** 160.69
*   **20-day Moving Average:** 155.78
*   **60-day Moving Average:** 154.59

*   *Analysis:* The current price is above all three moving averages (5, 20, and 60 days), suggesting a short-term upward trend. The positive change from the previous close further supports this. The price is up by 0.44, which is a small change.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 75.68 (Overbought)
*   **PPO:** 0.623
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **20-day Relative Deviation Change:** 3.7 (Positive - Short-term Increase)
*   **Expected Return:** -418.9% (Long-term, relative to S&P 500)

*   *Analysis:*
    *   The MRI indicates a low-risk environment.
    *   The RSI suggests the stock is currently overbought, potentially signaling a pullback.
    *   The positive change in relative deviation suggests improving short-term performance compared to its historical range.
    *   The "Hybrid Signal" recommends to buy, but with caution, indicating a moderately positive outlook.
    *   The extremely negative expected return is a significant red flag, suggesting very poor long-term performance relative to the S&P 500.

**4. Recent News & Significant Events**

*   **2025-07-17:** Major business developments, regulatory changes, or market events.
*   **2025-07-20:** Analyst discussions on performance and outlook, industry trends, and global economic factors.
*   **2025-07-19:** Stock volatility due to recent news, earnings reports, or executive actions.
*   **2025-07-18:** Mixed outlook with risks and opportunities, urging monitoring of news and announcements.

*   *Analysis:* Recent news indicates potential volatility and the need for careful monitoring of company-specific and broader market factors. The analysts are mixed on the outlook.

**5. Recent Earnings Analysis**

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-04-23   | 4.57 | 21.89 B$  |
| 2024-10-23   | 1.12 | 22.47 B$  |
| 2024-07-25   | 1.95 | 22.45 B$  |
| 2024-05-01   | 1.35 | 21.38 B$  |
| 2025-04-23   | 1.35 | 21.38 B$  |

*   *Analysis:* EPS shows volatility with the most recent EPS being significantly higher than previous quarters. Revenue remains relatively stable but shows some fluctuation.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |
| 2024-03-31   | $21.38B    | 69.55%        |

**Capital and Profitability**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-03-31   | $78.11B    | 14.08%   |
| 2024-12-31   | $71.49B    | 4.80%    |
| 2024-09-30   | $70.16B    | 3.84%    |
| 2024-06-30   | $71.54B    | 6.55%    |
| 2024-03-31   | $70.02B    | 4.65%    |

*   *Analysis:* Revenue is relatively stable. The profit margin has slightly decreased in the most recent quarter. Equity has increased significantly, along with ROE, in the most recent quarter, indicating improved profitability.

**7. Overall Summary and Recommendation**

Johnson & Johnson (JNJ) exhibits a mixed financial picture.

**Positive Aspects:**

*   **Short-term Positive Price Action:** The stock price is above its moving averages, suggesting a short-term upward trend.
*   **Low Market Risk:** The MRI indicates a low-risk environment.
*   **Strong ROE:** The most recent quarter shows a significant increase in ROE, indicating improved profitability.

**Negative Aspects:**

*   **Significant Underperformance vs. S&P 500:** JNJ has severely underperformed the S&P 500 over the period examined.
*   **Negative Expected Return:** The extremely negative expected return is a major concern.
*   **High Maximum Drawdown:** The high MDD indicates significant risk of loss.
*   **Recent Volatility:** News suggests recent volatility due to company-specific and market factors.
*   **Overbought RSI:** The RSI indicates that the stock might be overbought, potentially leading to a price correction.

**Recommendation:**

Given the significant underperformance relative to the S&P 500, the negative long-term expected return, and the recent volatility, a *cautious* approach is advised. While there are some positive short-term indicators, the long-term outlook is concerning. Investors should closely monitor upcoming earnings reports and news events for any signs of improvement in the company's long-term performance and profitability.
